Expert Interview
A Second Look: Discussing the potential of Cidara's once-weekly echinocandin, Rezzayo (rezafungin acetate) for the treatment and prevention of serious fungal infections
Ticker(s): CDTXInstitution: MD Anderson Cancer Center
- Director of the Mycology Research Program and Professor in the Department of Infectious Diseases Infection Control and Employee Health at MD Anderson.
- His research work is in the area of experimental and clinical mycology, antifungal drug resistance, pathogenesis, pharmacology and various aspects of epidemiology, diagnostics and treatment of fungal infections.
- He serves as an associate editor for Medical Mycology and sits in the editorial Boards of Antimicrobial Agents & Chemotherapy and Transplantation Infectious Diseases and has authored over 400 peer-reviewed manuscripts.
Please describe your background and practice setting.
Added By: chanell_adminHow many patients with invasive fungal infections do you manage?
Added By: chanell_adminWhat is the current standard of care for candidemia?
Added By: chanell_adminWhat are your thoughts on the potential of Cidara therapeutics antifungal rezafungin?
Added By: chanell_adminWhere would rezafungin fit into your current treatment algorithm?
Added By: chanell_adminRank your excitement for Rezafungin on a scale of 1-10?
Added By: chanell_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
